← ANALYST RATINGS · TIPRANKS
Vera Therapeutics (VERA): analyst forecast and price target
Analyst consensus
Strong Buy10 Buy2 Hold0 Sell
Ratings of 12 analysts in the last 3 months12-month forecast
Based on 12 price targets given in the last 3 months, the average target is $69.10, the highest $100, the lowest $34.00. The average is +147.8% from the last price of $27.88.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $27.00 → $28.00+3.7% | Hold | +0.4% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $27.00 → $28.00+3.7% | Hold | +0.4% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $27.00 → $28.00+3.7% | Hold | +0.4% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $27.00 → $28.00+3.7% | Hold | +0.4% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $28.00 → $29.00+3.6% | Hold | +4.0% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $26.00 → $27.00+3.8% | Hold | −3.2% | Upgrade | 17.10.26on TipRanks 05:06 | — | |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $70.00 | Buy | +151.1% | Reiterated | 15.10.26on TipRanks 07:40 | +6.6%next day −1.3% | ↗ |
| Unknown Analyst | Leerink Partners | $34.00 | Hold | +22.0% | Initiated | 12.10.26on TipRanks Oct 13 12:05 | −7.2%next day −3.3% | ↗ |
| Dina Ramadane★★★★★★★★★★#5584 · hits 75% · avg +7.8% | Bank of America Securities | $66.00 → $60.00−9.1% | Buy | +115.2% | Reiterated | 09.10.26on TipRanks 06:55 | −0.1%next day −7.2% · 5 days −4.7% | ↗ |
| Arthur He CFA★★★★★★★★★★#323 · hits 58% · avg +36.5% | H.C. Wainwright | $90.00 | Buy | +222.8% | Reiterated | 01.10.26on TipRanks 10:35 | −4.2%next day −2.6% · 5 days −5.4% | ↗ |
| Unknown Analyst | Jefferies | $59.00 | Buy | +111.6% | Reiterated | 16.09.26on TipRanks Sep 23 21:00 | −5.2%next day +6.7% · 5 days +2.0% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $34.00 | Hold | +22.0% | Reiterated | 16.09.26on TipRanks 08:09 | −5.2%next day +6.7% · 5 days +2.0% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | — | Buy | — | Reiterated | 15.09.26on TipRanks Sep 16 07:06 | −0.7%next day −5.2% · 5 days +5.3% | ↗ |
| Rami Katkhuda★★★★★★★★★★#297 · hits 55% · avg +31.7% | LifeSci Capital | $90.00 | Buy | +222.8% | Reiterated | 15.09.26on TipRanks 11:25 | −0.7%next day −5.2% · 5 days +5.3% | ↗ |
| Ryan Deschner★★★★★★★★★★#506 · hits 69% · avg +41.7% | Raymond James | — | Buy | — | Reiterated | 15.09.26on TipRanks 10:15 | −0.7%next day −5.2% · 5 days +5.3% | ↗ |
| Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% | TD Cowen | $78.00 | Buy | +179.8% | Reiterated | 31.08.26on TipRanks 10:50 | 0.0%next day +1.1% · 5 days +3.7% | ↗ |
| Vamil Divan★★★★★★★★★★#458 · hits 59% · avg +13.5% | Guggenheim | $76.00 | Buy | +172.6% | Reiterated | 14.08.26on TipRanks Aug 17 07:32 | +9.7%next day +0.5% · 5 days +3.4% | ↗ |
| Pete Stavropoulos★★★★★★★★★★#2065 · hits 45% · avg +16.4% | Cantor Fitzgerald | $100 | Buy | +258.7% | Reiterated | 10.08.26on TipRanks Aug 11 07:55 | −4.0%next day −3.8% · 5 days +0.2% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $91.00 | Buy | +226.4% | Reiterated | 09.07.26on TipRanks 09:12 | −0.8%next day −1.5% · 5 days −7.7% | ↗ |
| Paul Choi★★★★★★★★★★#1415 · hits 56% · avg +9.6% | Goldman Sachs | $90.00 | Buy | +222.8% | Reiterated | 05.06.26on TipRanks Jun 3 09:15 | +0.7%next day +6.4% · 5 days +4.9% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | $88.00 | Buy | +215.6% | Reiterated | 02.06.26on TipRanks Jun 3 09:08 | −8.0%next day +0.7% · 5 days +4.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Vera Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $75.40 at a price of $32.29 (+133.5%); now: $69.10 at $27.88 (+147.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 15 | 25 | 31 | 29 | 22 |
| Buy | 1 | 4 | 4 | 4 | 3 | 2 |
| Hold | 1 | 1 | 3 | 4 | 5 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.61 (from $-1.80 to $-1.39). Last quarter: $-1.52.
Best top-analyst consensus in the sector · Healthcare
About Vera Therapeutics
- CEO: Marshall Fordyce
- Employees: 361
- 2000 Sierra Point Parkway, Brisbane, CA, 94005, US
- veratx.com
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Data from the stock’s TipRanks forecast page, read 24 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗